Tag Archives: corporate integrity agreements

Home / Posts tagged "corporate integrity agreements"

Prosecutorial Discretion

We (Bob Thomas and Suzanne Durrell) were both federal prosecutors in our not so distant past, and we work with federal prosecutors every day.  One of the least understood aspects of criminal law is prosecutorial discretion, the leeway given to prosecutors to make judgment calls that have huge impacts on the lives of people and companies.  On the criminal side, they (prosecutors) get to decide whom to charge with what offense, whom not to charge, whom to immunize, whom to seek the death penalty against, and so forth.

 

On the civil side, where we now operate more frequently with our False Claims Act whistleblower practice, they get to decide whether to intervene in a case, which theories of liability to run with and which to jettison, which individuals to pursue civilly and which to let slip, what amount of money to settle a case for, which companies and individuals to try to exclude from future participation in the Medicare and Medicaid programs, and so forth.

 

The list of areas where prosecutorial discretion surfaces is quite long.  And in fact, it is hard to imagine a job that a person could have in their late twenties or early thirties where he or she could have so much discretionary power over other people’s lives.  It’s one of the reasons young lawyers love being Assistant U.S. Attorneys:  they get to have relevant professional lives that have real impact, at a relatively early stage of their careers.

 

But the dark side of this reality is that prosecutors can do enormous damage in the exercise of their discretion, which is essentially unreviewable.  This New York Times piece yesterday gave a good example.  On the criminal side of the house, the use of the Section 851 mandatory minimum sentencing enhancements can give prosecutors enormous leverage to force defendants to plead guilty when they would otherwise go to trial.  Sometimes the use of this leverage is inoffensive; other times it can be deeply troubling and lead to unjust results.

 

We now incarcerate a higher percentage of our population than any other industrialized nation in the world, with disproportionate numbers of the prison population being people of color.  Congress, in its zeal to show how tough it could be on drug crime, passed many sentencing “enhancement” laws in the 1980’s that caused sentences to go well beyond the structured sentencing schemes put in place by the federal Sentencing Commission and the guidelines it promulgated.  Section 851 was one of those “enhancements,” and one that should be re-evaluated.

 

On the civil side of the house, an area of fertile debate is the government’s discretionary power to settle large cases against companies for monetary fines and civil damages only, without going after the individuals behind the corporate schemes. In the Pfizer case, for example, the then-record $2.3 billion settlement was impressive indeed, but the judge overseeing the case went out of his way to question prosecutors how $2.3 billion worth of fraud could not result in any individuals being held accountable.  Judge Rakoff in the Southern District of New York has also been a frequent critic of these corporate deals, in one instance rejecting a proposed settlement reached between the government and a bank defendant as too friendly to the bank and lacking in any actual admissions of wrong-doing.

 

So prosecutorial discretion is one of the things that makes the job of a prosecutor challenging and fun. But the wide latitude it gives individual lawyers, with relatively little oversight, can also lead to bad outcomes, or results that leave many questions still to be answered.

Fifteenth Annual Pharma Congress 2014

Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum (The 2014 Pharma Congress),
November 3-5, 2014, Hyatt Regency, Capitol Hill, Washington, D.C.

 

Attorney Suzanne E. Durrell, Durrell Law Office

Attorney Suzanne E. Durrell, Durrell Law Office

Suzanne Durrell to join the /Qui Tam/ panel at the upcoming Fifteenth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum – www.PharmaCongress.com

 

November 3 – 5, 2014, Hyatt Regency on Capitol Hill in Washington, DC. The Congress is by far the largest annual gathering of pharmaceutical company compliance professional and in-house counsel and is attended by approximately 400 annually.

 

The Pharmaceutical Compliance Forum (PCF) is a coalition of senior compliance professionals and legal counsel from more than 50 of the largest research based pharmaceutical manufacturers. The PCF was founded in early-1999 by compliance professionals from the pharmaceutical industry to promote effective corporate compliance programs. The members meet twice a year, for two days, focusing on open and informal sharing of compliance information, best practices, and current developments in the field.

PCF also sponsors a three-day compliance congress each Fall. Learn more.

Related: Corporate Integrity Agreements can be the basis for a False Claims Act Case (PDF paper),  by Suzanne E. Durrell, Esq. – Washington DC, November 2014